Chem Reports estimates that the 23-Valent Pneumococcal Polysaccharide Vaccine (PPSV23) Market was valued at USD XXX million in 2025 and is projected to reach USD XXX million by 2036, expanding at a CAGR of XX% over the forecast period.
The 23-valent pneumococcal polysaccharide vaccine (PPSV23) provides protection against 23 serotypes of Streptococcus pneumoniae. It is widely recommended for adults aged 65 years and older, immunocompromised populations, and individuals with chronic health conditions. PPSV23 remains an essential component of adult immunization programs globally.
PPSV23 plays a significant role in preventing invasive pneumococcal diseases (IPD), including bacteremia and meningitis. While conjugate pneumococcal vaccines (PCVs) have gained prominence, PPSV23 continues to be recommended for broader serotype coverage in adult populations.
Market growth is influenced by:
Aging global population
Expansion of adult vaccination programs
Government immunization mandates
Increasing awareness of pneumococcal disease burden
Public health preparedness initiatives
COVID-19 initially disrupted routine immunization campaigns but subsequently increased awareness regarding respiratory disease prevention, supporting long-term vaccination uptake.
Single-dose vial
Pre-filled syringe
Multi-dose vial
Lyophilized formulations
Pre-filled syringes are gaining share due to ease of administration and reduced contamination risk.
Pediatric (2–10 years, high-risk groups only)
Adolescents & Adults (10–64 years, risk-based)
Elderly (≥65 years)
The elderly population represents the dominant revenue segment due to high susceptibility and national vaccination guidelines.
Public immunization programs
Hospital pharmacies
Retail pharmacies
Government procurement tenders
International health agencies
Public sector procurement accounts for the majority of global volumes.
Hospitals
Community clinics
Long-term care facilities
Vaccination centers
High adult vaccination coverage
Strong reimbursement frameworks
Established immunization guidelines
Increasing adult booster recommendations
Government-funded immunization programs
Growing elderly demographic
Expanding healthcare access
Rising awareness of adult immunization
Increasing government vaccination initiatives
Improving immunization infrastructure
Public health campaigns targeting elderly populations
Gradual expansion of vaccination coverage
International health partnerships supporting procurement
North America and Europe maintain high penetration rates, while Asia-Pacific is expected to exhibit the fastest growth.
Merck & Co., Inc.
Sanofi
China National Biotec Group (CNBG)
Walvax Biotechnology
Serum Institute of India
Beijing Minhai Biotechnology
SK Bioscience
Sinovac Biotech
Bio Farma
GlaxoSmithKline (limited polysaccharide portfolio presence in pneumococcal category)
The market is relatively concentrated, with a limited number of global suppliers due to complex manufacturing and regulatory barriers.
Competitive Rivalry – Moderate
Limited number of approved manufacturers reduces fragmentation, but pricing competition exists in tender-based markets.
Threat of New Entrants – Low
High regulatory, clinical, and manufacturing barriers restrict new participants.
Bargaining Power of Suppliers – Moderate
Raw materials and biologic processing inputs require strict quality control but are not highly fragmented.
Bargaining Power of Buyers – High
Governments and global health organizations negotiate pricing through bulk procurement.
Threat of Substitutes – Moderate to High
Pneumococcal conjugate vaccines (PCVs) present competitive pressure, especially in pediatric segments.
Strengths
Broad serotype coverage (23 strains)
Established clinical use
Strong inclusion in adult immunization guidelines
Weaknesses
Lower immunogenicity in certain age groups compared to conjugate vaccines
Limited booster response
Declining pediatric use
Opportunities
Expansion of adult immunization programs
Combination vaccine strategies
Growth in emerging markets
Increased focus on preventive healthcare
Threats
Increasing adoption of higher-valent conjugate vaccines
Pricing pressure from public tenders
Regulatory shifts in vaccination recommendations
Gradual shift toward sequential vaccination strategies (PCV followed by PPSV23)
Rising focus on elderly and high-risk population immunization
Expansion of domestic vaccine manufacturing in Asia
Integration of adult vaccines into national immunization schedules
Growth in public awareness campaigns
Aging global population
Rising incidence of respiratory infections
Strengthening public health policies
Increased healthcare expenditure
Post-pandemic vaccination awareness
Competition from next-generation conjugate vaccines
Pricing constraints in low-income countries
Cold chain logistics requirements
Regulatory complexity across regions
Antigen cultivation & polysaccharide extraction
Purification and quality testing
Formulation and filling
Cold chain storage
Government tender procurement
Distribution to healthcare providers
Administration & monitoring
Value concentration is highest in antigen development, regulatory approval, and large-scale biologics manufacturing.
Invest in cost-efficient production technologies
Strengthen government tender relationships
Explore combination or sequential immunization strategies
Monitor transition dynamics between polysaccharide and conjugate vaccines
Focus on emerging market manufacturers with expanding capacity
Enhance adult vaccination awareness
Improve immunization tracking systems
Strengthen cold chain infrastructure
Partner with national immunization programs
1. Market Overview of 23-Valent Pneumococcal Polysaccharide Vaccine
1.1 23-Valent Pneumococcal Polysaccharide Vaccine Market Overview
1.1.1 23-Valent Pneumococcal Polysaccharide Vaccine Product Scope
1.1.2 Market Status and Outlook
1.2 23-Valent Pneumococcal Polysaccharide Vaccine Market Size by Regions:
1.3 23-Valent Pneumococcal Polysaccharide Vaccine Historic Market Size by Regions
1.4 23-Valent Pneumococcal Polysaccharide Vaccine Forecasted Market Size by Regions
1.5 Covid-19 Impact on Key Regions, Keyword Market Size YoY Growth
1.5.1 North America
1.5.2 East Asia
1.5.3 Europe
1.5.4 South Asia
1.5.5 Southeast Asia
1.5.6 Middle East
1.5.7 Africa
1.5.8 Oceania
1.5.9 South America
1.5.10 Rest of the World
1.6 Coronavirus Disease 2019 (Covid-19) Impact Will Have a Severe Impact on Global Growth
1.6.1 Covid-19 Impact: Global GDP Growth, 2019, 2020 and 2021 Projections
1.6.2 Covid-19 Impact: Commodity Prices Indices
1.6.3 Covid-19 Impact: Global Major Government Policy
2. Covid-19 Impact 23-Valent Pneumococcal Polysaccharide Vaccine Sales Market by Type
2.1 Global 23-Valent Pneumococcal Polysaccharide Vaccine Historic Market Size by Type
2.2 Global 23-Valent Pneumococcal Polysaccharide Vaccine Forecasted Market Size by Type
2.3 Single Dose Vial
2.4 Pre-filled Syringe
3. Covid-19 Impact 23-Valent Pneumococcal Polysaccharide Vaccine Sales Market by Application
3.1 Global 23-Valent Pneumococcal Polysaccharide Vaccine Historic Market Size by Application
3.2 Global 23-Valent Pneumococcal Polysaccharide Vaccine Forecasted Market Size by Application
3.3 For Children (2-10)
3.4 For Person (10-64)
3.5 For The Old (?65)
4. Covid-19 Impact Market Competition by Manufacturers
4.1 Global 23-Valent Pneumococcal Polysaccharide Vaccine Production Capacity Market Share by Manufacturers
4.2 Global 23-Valent Pneumococcal Polysaccharide Vaccine Revenue Market Share by Manufacturers
4.3 Global 23-Valent Pneumococcal Polysaccharide Vaccine Average Price by Manufacturers
5. Company Profiles and Key Figures in 23-Valent Pneumococcal Polysaccharide Vaccine Business
5.1 MSD
5.1.1 MSD Company Profile
5.1.2 MSD 23-Valent Pneumococcal Polysaccharide Vaccine Product Specification
5.1.3 MSD 23-Valent Pneumococcal Polysaccharide Vaccine Production Capacity, Revenue, Price and Gross Margin
5.2 Sanofipasteur
5.2.1 Sanofipasteur Company Profile
5.2.2 Sanofipasteur 23-Valent Pneumococcal Polysaccharide Vaccine Product Specification
5.2.3 Sanofipasteur 23-Valent Pneumococcal Polysaccharide Vaccine Production Capacity, Revenue, Price and Gross Margin
5.3 CDIBP
5.3.1 CDIBP Company Profile
5.3.2 CDIBP 23-Valent Pneumococcal Polysaccharide Vaccine Product Specification
5.3.3 CDIBP 23-Valent Pneumococcal Polysaccharide Vaccine Production Capacity, Revenue, Price and Gross Margin
6. North America
6.1 North America 23-Valent Pneumococcal Polysaccharide Vaccine Market Size
6.2 North America 23-Valent Pneumococcal Polysaccharide Vaccine Key Players in North America
6.3 North America 23-Valent Pneumococcal Polysaccharide Vaccine Market Size by Type
6.4 North America 23-Valent Pneumococcal Polysaccharide Vaccine Market Size by Application
7. East Asia
7.1 East Asia 23-Valent Pneumococcal Polysaccharide Vaccine Market Size
7.2 East Asia 23-Valent Pneumococcal Polysaccharide Vaccine Key Players in North America
7.3 East Asia 23-Valent Pneumococcal Polysaccharide Vaccine Market Size by Type
7.4 East Asia 23-Valent Pneumococcal Polysaccharide Vaccine Market Size by Application
8. Europe
8.1 Europe 23-Valent Pneumococcal Polysaccharide Vaccine Market Size
8.2 Europe 23-Valent Pneumococcal Polysaccharide Vaccine Key Players in North America
8.3 Europe 23-Valent Pneumococcal Polysaccharide Vaccine Market Size by Type
8.4 Europe 23-Valent Pneumococcal Polysaccharide Vaccine Market Size by Application
9. South Asia
9.1 South Asia 23-Valent Pneumococcal Polysaccharide Vaccine Market Size
9.2 South Asia 23-Valent Pneumococcal Polysaccharide Vaccine Key Players in North America
9.3 South Asia 23-Valent Pneumococcal Polysaccharide Vaccine Market Size by Type
9.4 South Asia 23-Valent Pneumococcal Polysaccharide Vaccine Market Size by Application
10. Southeast Asia
10.1 Southeast Asia 23-Valent Pneumococcal Polysaccharide Vaccine Market Size
10.2 Southeast Asia 23-Valent Pneumococcal Polysaccharide Vaccine Key Players in North America
10.3 Southeast Asia 23-Valent Pneumococcal Polysaccharide Vaccine Market Size by Type
10.4 Southeast Asia 23-Valent Pneumococcal Polysaccharide Vaccine Market Size by Application
11. Middle East
11.1 Middle East 23-Valent Pneumococcal Polysaccharide Vaccine Market Size
11.2 Middle East 23-Valent Pneumococcal Polysaccharide Vaccine Key Players in North America
11.3 Middle East 23-Valent Pneumococcal Polysaccharide Vaccine Market Size by Type
11.4 Middle East 23-Valent Pneumococcal Polysaccharide Vaccine Market Size by Application
12. Africa
12.1 Africa 23-Valent Pneumococcal Polysaccharide Vaccine Market Size
12.2 Africa 23-Valent Pneumococcal Polysaccharide Vaccine Key Players in North America
12.3 Africa 23-Valent Pneumococcal Polysaccharide Vaccine Market Size by Type
12.4 Africa 23-Valent Pneumococcal Polysaccharide Vaccine Market Size by Application
13. Oceania
13.1 Oceania 23-Valent Pneumococcal Polysaccharide Vaccine Market Size
13.2 Oceania 23-Valent Pneumococcal Polysaccharide Vaccine Key Players in North America
13.3 Oceania 23-Valent Pneumococcal Polysaccharide Vaccine Market Size by Type
13.4 Oceania 23-Valent Pneumococcal Polysaccharide Vaccine Market Size by Application
14. South America
14.1 South America 23-Valent Pneumococcal Polysaccharide Vaccine Market Size
14.2 South America 23-Valent Pneumococcal Polysaccharide Vaccine Key Players in North America
14.3 South America 23-Valent Pneumococcal Polysaccharide Vaccine Market Size by Type
14.4 South America 23-Valent Pneumococcal Polysaccharide Vaccine Market Size by Application
15. Rest of the World
15.1 Rest of the World 23-Valent Pneumococcal Polysaccharide Vaccine Market Size
15.2 Rest of the World 23-Valent Pneumococcal Polysaccharide Vaccine Key Players in North America
15.3 Rest of the World 23-Valent Pneumococcal Polysaccharide Vaccine Market Size by Type
15.4 Rest of the World 23-Valent Pneumococcal Polysaccharide Vaccine Market Size by Application
16 23-Valent Pneumococcal Polysaccharide Vaccine Market Dynamics
16.1 Covid-19 Impact Market Top Trends
16.2 Covid-19 Impact Market Drivers
16.3 Covid-19 Impact Market Challenges
16.4 Porter?s Five Forces Analysis
18 Regulatory Information
17 Analyst's Viewpoints/Conclusions
18 Appendix
18.1 Research Methodology
18.1.1 Methodology/Research Approach
18.1.2 Data Source
18.2 Disclaimer
Single-dose vial
Pre-filled syringe
Multi-dose vial
Lyophilized formulations
Pre-filled syringes are gaining share due to ease of administration and reduced contamination risk.
Pediatric (2–10 years, high-risk groups only)
Adolescents & Adults (10–64 years, risk-based)
Elderly (≥65 years)
The elderly population represents the dominant revenue segment due to high susceptibility and national vaccination guidelines.
Public immunization programs
Hospital pharmacies
Retail pharmacies
Government procurement tenders
International health agencies
Public sector procurement accounts for the majority of global volumes.
Hospitals
Community clinics
Long-term care facilities
Vaccination centers
Upto 24 to 48 hrs (Working Hours)
Upto 72 hrs max (Working Hours) - Weekends and Public Holidays
Single User License - Allows access to only one person to the report.
Multi User License - Allows sharing with max 5 persons within organization.
Corporate License – Can be shared across entire organization.
Online Payments with PayPal
Wire Transfer / Bank Transfer
At ChemReports, we understand that business decisions can’t wait. Our research specialists are available anytime to answer your queries and guide you through our reports, ensuring quick and reliable assistance.
ChemReports provides 360° market analysis across materials, technologies, and global chemical sectors—helping you make confident business decisions.
We turn complex data into strategic insights to support fact-based decisions, market entry strategies, and competitive analysis.
Your personal and business information is completely secure with us. We value your trust and ensure strict confidentiality.
Need tailored insights? Our analysts provide custom reports built on authentic data and aligned with your specific business goals.